Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Escalation Study of SLV334 in Moderate and Severe Traumatic Brain Injury
2008-001409-40Phase 2Completed
- Sponsor
- Solvay Pharmaceuticals
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in traumatic brain injury (TBI) comparing SLV334 with Placebo (2 arms). Primary endpoint: Safety and tolerability of SLV334. Started Nov 2008; status: completed.
02
Drugs
slv-334
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2008-001409-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001409-40.